1405 related articles for article (PubMed ID: 25689424)
1. Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine.
Skalova S; Svadlakova T; Shaikh Qureshi WM; Dev K; Mokry J
Int J Mol Sci; 2015 Feb; 16(2):4043-67. PubMed ID: 25689424
[TBL] [Abstract][Full Text] [Related]
2. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
3. Induced pluripotency and direct reprogramming: a new window for treatment of neurodegenerative diseases.
Li R; Bai Y; Liu T; Wang X; Wu Q
Protein Cell; 2013 Jun; 4(6):415-24. PubMed ID: 23686735
[TBL] [Abstract][Full Text] [Related]
4. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Qi SD; Smith PD; Choong PF
ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
[TBL] [Abstract][Full Text] [Related]
5. [Progress in induced pluripotent stem cell research for age-related neurodegenerative diseases].
Ito D; Yagi T; Suzuki N
Brain Nerve; 2013 Mar; 65(3):283-8. PubMed ID: 23475520
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
[TBL] [Abstract][Full Text] [Related]
7. Present and future challenges of induced pluripotent stem cells.
Ohnuki M; Takahashi K
Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20140367. PubMed ID: 26416678
[TBL] [Abstract][Full Text] [Related]
8. Current status of treating neurodegenerative disease with induced pluripotent stem cells.
Pen AE; Jensen UB
Acta Neurol Scand; 2017 Jan; 135(1):57-72. PubMed ID: 26748435
[TBL] [Abstract][Full Text] [Related]
9. The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases.
Peng J; Zeng X
Stem Cell Res Ther; 2011 Jul; 2(4):32. PubMed ID: 21861938
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in iPSC technologies involving cardiovascular and neurodegenerative disease modeling.
Csöbönyeiová M; Danišovič Ľ; Polák Š
Gen Physiol Biophys; 2016 Jan; 35(1):1-12. PubMed ID: 26492069
[TBL] [Abstract][Full Text] [Related]
11. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
Qi SD; Smith PD; Choong PF
ANZ J Surg; 2014 Jun; 84(6):E1-11. PubMed ID: 23035845
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in Porcine Pluripotent Cells: From ICM to iPSCs.
Kim E; Hyun SH
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27626414
[TBL] [Abstract][Full Text] [Related]
13. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
Hu C; Li L
Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
[TBL] [Abstract][Full Text] [Related]
14. Evolution of induced pluripotent stem cell technology.
Zhou H; Ding S
Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
[TBL] [Abstract][Full Text] [Related]
15. An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.
Menon S; Shailendra S; Renda A; Longaker M; Quarto N
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805822
[TBL] [Abstract][Full Text] [Related]
16. Advances in reprogramming-based study of neurologic disorders.
Nityanandam A; Baldwin KK
Stem Cells Dev; 2015 Jun; 24(11):1265-83. PubMed ID: 25749371
[TBL] [Abstract][Full Text] [Related]
17. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications.
Das AK; Pal R
J Tissue Eng Regen Med; 2010 Aug; 4(6):413-21. PubMed ID: 20084623
[TBL] [Abstract][Full Text] [Related]
18. iPSCs, aging and age-related diseases.
Isobe K; Cheng Z; Nishio N; Suganya T; Tanaka Y; Ito S
N Biotechnol; 2014 Sep; 31(5):411-21. PubMed ID: 24784583
[TBL] [Abstract][Full Text] [Related]
19. Veterinary applications of induced pluripotent stem cells: regenerative medicine and models for disease?
Cebrian-Serrano A; Stout T; Dinnyes A
Vet J; 2013 Oct; 198(1):34-42. PubMed ID: 24129109
[TBL] [Abstract][Full Text] [Related]
20. Synthetic sulfonyl-hydrazone-1 positively regulates cardiomyogenic microRNA expression and cardiomyocyte differentiation of induced pluripotent stem cells.
Quattrocelli M; Palazzolo G; Agnolin I; Martino S; Bouché M; Anastasia L; Sampaolesi M
J Cell Biochem; 2011 Aug; 112(8):2006-14. PubMed ID: 21445862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
